All In Biotech

Drug Trial Radar · NCT03768960

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

150

Actual

Start

Jun 10, 2019

Primary completion

Jul 16, 2022

Study completion Jul 16, 2022

Sponsor

Lead sponsor
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent.

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAE)Time frame: Approximately up to 29 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Avron Hospitals Pvt. Ltd

    Ahmedabad, India

  • M S Ramaiah Medical College and Hospital

    Bengaluru, India

  • Apollo Hospitals

    Bhubaneswar, India

  • Sparsh Hospitals & Critical Care (Pvt) Ltd

    Bhubaneswar, India

  • Post Graduate Institute of Medical Education And Research PGIMER

    Chandigarh, India

  • Apollo Hospitals

    Hyderabad, India

  • Basavatarakam Indo-American Hospital

    Hyderabad, India

  • Cytecare Hospitals Pvt. Ltd

    Karnataka, India

  • Tata Medical Center

    Kolkata, India

  • Shatabdi Super Speciality Hospital

    Mumbai Naka, India

  • Kingsway Hospital

    Nagpur, India

  • Apex Wellness Hospital

    Nashik, India

  • All India Institute of Medical Sciences

    New Delhi, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, India

  • Deenanath Mangeshkar Hospital and Research Centre

    Pune, India

  • Noble Hospital Pvt Ltd

    Pune, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.